Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.59 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | PTAFR | P25105 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7753858 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1RECQLMAPT | |
| SCHEMBL479274 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1RECQLMAPT | |
| SCHEMBL479199 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1RECQLMAPT | |
| SCHEMBL672865 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1RECQLMAPT | |
| SCHEMBL479150 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1RECQLMAPT | |
| SCHEMBL14967280 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1RECQLMAPT | |
| SCHEMBL673766 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2NR5A2NR5A1RECQLMAPT | |
| SCHEMBL2930405 | 0.96 | SMN1; SMN2 (0.55) | SMN1; SMN2NR5A2NR5A1RECQLMAPT | |
| SCHEMBL37559 | 0.94 | ALDH1A1 (0.60) | SMN1; SMN2NR5A2NR5A1RECQLMAPT | |
| SCHEMBL672371 | 0.94 | ALDH1A1 (0.60) | SMN1; SMN2NR5A2NR5A1RECQLMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4577196-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | Popvax Private Limited (IN) | 2025-07-02 | — | — | EP | claimed |
| WO-2024216162-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | STRAND THERAPEUTICS INC. (US) | 2024-10-17 | — | — | WO | claimed |
| WO-2024044178-A1 | LIPID NANOPARTICLE (LNP) COMPOSITION OR FORMULATION FOR NUCLEIC ACID THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2024-02-29 | — | — | WO | claimed |
| EP-3787607-A1 | CAROTENOID COMPOSITIONS AND USES THEREOF | L.E.A.F Holdings Group LLC (US) | 2021-03-10 | — | — | EP | claimed |
| EP-3458092-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| EP-3458083-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | claimed |
| WO-2017201352-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2017201350-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | claimed |
| WO-2010030730-A1 | POLYETHYLENE GLYCOL LIPID CONJUGATES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | WO | claimed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| EP-1845944-A2 | PHARMACEUTICAL COMPOSITIONS | ID Biomedical Corporation of Quebec c.o.b. as Glaxosmithkline Biologicals North America (CA) | 2007-10-24 | — | — | EP | claimed |
| WO-2006086330-A2 | PHARMACEUTICAL COMPOSITIONS | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2006-08-17 | — | — | WO | claimed |
| WO-2026090590-A1 | NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE | Remedium Bio, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4695401-A1 | SYNTHETIC CIRCUITS AND USES THEREOF | Strand Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| WO-2025229403-A1 | LIPID COMPOSITIONS AND METHODS OF USE THEREOF | CAMURUS AB (SE) | 2025-11-06 | — | — | WO | disclosed |
| WO-2007095175-A2 | THERMO-RESPONSIVE MATERIALS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-08-23 | — | — | WO | disclosed |
| WO-2006096701-A2 | PHARMACEUTICAL LIPOSOMAL COMPOSITIONS | ID BIOMEDICAL CORPORATION OF QUEBEC C.O.B. AS GLAXOSMITHKLINE BIOLOGICALS NORTH AMERICA (CA) | 2006-09-14 | — | — | WO | disclosed |
| EP-1458752-A2 | POLYPEPTIDES OF PSEUDOMONAS AERUGINOSA | Shire Biochem Inc. (CA) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003042240-A2 | POLYPEPTIDES OF PSEUDOMONAS AERUGINOSA | SHIRE BIOCHEM INC. (CA) | 2003-05-22 | — | — | WO | disclosed |